Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?

被引：2
|
作者：
Catanese, Silvia [1 ,2 ]
Lordick, Florian [2 ]
机构：
[1] Univ Pisa, Azienda Osped Univ Pisana AOUP, Dept Med Oncol, Pisa, Italy
[2] Univ Leipzig, Univ Canc Ctr Leipzig UCCL, Med Ctr, Dept Med Oncol Gastroenterol Hepatol Pulmonol & I, Leipzig, Germany
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 24期
关键词：
2ND-LINE THERAPY; DOUBLE-BLIND; OPEN-LABEL; PHASE-III; SORAFENIB; MULTICENTER; CAMRELIZUMAB;
D O I：
10.21037/atm-20-4438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Auranofin and the efficacy of anti-PD1 immunotherapy
    Zhang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] A future boost for anti-PD1 responses
    Stower, Hannah
    NATURE MEDICINE, 2020, 26 (09) : 1331 - 1331
  • [43] Anti-PD1 therapy with nivolumab in sarcoma
    Paoluzzi, L.
    Cacavio, A.
    Ghesani, M.
    Karambelkar, A.
    Rapkiewicz, A.
    Rosen, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] A future boost for anti-PD1 responses
    Hannah Stower
    Nature Medicine, 2020, 26 : 1331 - 1331
  • [45] Effectiveness of anti-PD-1 for hepatocellular carcinoma Reply
    Qin, Shukui
    Ren, Zhenggang
    Meng, Zhiqiang
    Chen, Zhendong
    Chai, Xiaoli
    LANCET ONCOLOGY, 2020, 21 (06): : E294 - E294
  • [46] Anti-PD1 antibodies in the adjuvant setting
    Dreno, B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 14 - 14
  • [47] Biomarkers of Anti-PD1 Therapy in Mesothelioma
    Baas, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S181 - S182
  • [48] PKCα/JZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma
    Wei, Chuan-Yuan
    Zhu, Meng-Xuan
    Zhang, Peng-Fei
    Huang, Xiao-Yong
    Wan, Jin-Kai
    Yao, Xiu-Zhong
    Hu, Ze-Tao
    Chai, Xiao-Qiang
    Peng, Rui
    Yang, Xuan
    Gao, Chao
    Gao, Jian
    Wang, Si-Wei
    Zheng, Yi-Min
    Tang, Zheng
    Gao, Qiang
    Zhou, Jian
    Fan, Jia-Bin
    Ke, Ai-Wu
    Fan, Jia
    JOURNAL OF HEPATOLOGY, 2022, 77 (01) : 163 - 176
  • [49] Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling
    Yu, Chao
    Zhang, Xinyi
    Wang, Min
    Xu, Gaoxin
    Zhao, Siqi
    Feng, Yongheng
    Pan, Chao
    Yang, Weijun
    Zhou, Jin
    Shang, Longcheng
    Ma, Yong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
    Qiaoyun Tan
    Liyuan Dai
    Yanrong Wang
    Shuxia Liu
    Te Liang
    Rongrong Luo
    Shasha Wang
    Ning Lou
    Haizhu Chen
    Yu Zhou
    Qiaofeng Zhong
    Jianliang Yang
    Puyuan Xing
    Xingsheng Hu
    Yutao Liu
    Shengyu Zhou
    Jiarui Yao
    Di Wu
    Zhishang Zhang
    Le Tang
    Xiaobo Yu
    Xiaohong Han
    Yuankai Shi
    Cancer Immunology, Immunotherapy, 2022, 71 : 1681 - 1691
12345